Bayer has failed to block an Indian generic rival from exporting an erectile dysfunction drug in a case that one observer says breaks new ground in considering how to weigh public interest issues relating to the grant or not of patent-based injunctions. The ruling comes ahead of an annual pitched battle over the country’s pharmaceutical patent laws, as well as IAM’s first conference in the country at the end of this month.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM is a high quality magazine with in-depth articles about intellectual asset management not found in any other publication. It adds value to our profession!

Katharine Ku
Director of the office of technology licensing
Stanford University


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?